Biotech IPOs Pull in $7.5B Across 22 Deals in 2026, While Market Gains Stall in Q3
Biopharma companies raised about $7.5 billion from 22 initial public offerings in the first three quarters of 2026, according to J.P. Morgan data. This level of financing far exceeds the eight offerings recorded in 2025.
Despite the strong IPO activity, the broader biotech market showed little movement in the third quarter. The SPDR S&P Biotech ETF (XBI) is up roughly 29.6% for the year but was flat, down less than 1%, in Q3, while the Nasdaq and S&P 500 each posted modest gains of just over 2%.
The contrast highlights a split trend: robust capital raising for biotech firms alongside a muted public‑market rally. Overall, the sector’s public‑market performance for the year remains positive, but the recent quarter’s flatness suggests investors are exercising caution after earlier gains.
This writeup was produced by pharmadog from original reporting by BioSpace.
Original headline: “Biotech IPOs raise $7.5B as sector’s performance rally flattens”
read at BioSpace ↗
comments(0)
5-min edit window · permanent after that